China Offers Playground Of Opportunity For Trying Out Different Models, Risks - Shanghai R&D Summit
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The rapid transformation of China's pharmaceutical and biotech sector reveals the changing face of this nation and the realization that China is more dynamic than developed markets such as the U.S. and Europe and is a good place to try out different models and approaches to R&D, presenters at the China R&D Summit told attendees April 7
You may also be interested in...
PPD's Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 1 Of 2)
Lee Babiss left Roche, one of the world's largest pharmaceutical companies, for a contract research organization position in part because his days as president of drug research were filled less with driving research projects forward and more with containing his group's costs, a reflection of the current state of R&D productivity at major pharmaceutical firms.
PPD's Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 1 Of 2)
Lee Babiss left Roche, one of the world's largest pharmaceutical companies, for a contract research organization position in part because his days as president of drug research were filled less with driving research projects forward and more with containing his group's costs, a reflection of the current state of R&D productivity at major pharmaceutical firms.
PPD's Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 1 Of 2)
Babiss speaks of the evolving relationships between pharmaceutical firms and CROs, including end-to-end virtualization of R&D.